The Cubs have traditionally taken a file-and-trial approach to arbitration, even though teams and players are free to reach ...

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Now, the Cubs can turn their focus to pitching. They need a little bit of help in their bullpen, even after acquiring Eli ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target remains the same with $1,100.00. Discover the latest ...

Starting pitcher Matthew Boyd received a two-year deal in free agency and his Cleveland Guardians teammate, Eli Morgan, was acquired in a trade to bolster the bullpen. Still in the Roki Sasaki swe ...

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...

To this point, the only notable moves the Cubs have made in either department were a trade with the Cleveland Guardians for reliever Eli Morgan as well as signing starter Matthew Boyd on a two ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

Eli Lilly projects double-digit revenue growth through early 2030s, and Bristol-Myers expects $10B in peak sales from its schizophrenia drug According to JP Morgan, U.S. large-cap biopharma stocks ...

One of these relievers, Eli Morgan, was severely underrated all season but continually showed that he has the stuff. A starter in his 2021 rookie season, Morgan was moved to the bullpen in 2022 as ...